These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

636 related articles for article (PubMed ID: 16394286)

  • 61. Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy.
    Wu P; Liu S; Zhang W; Zhang Y; Zhu G; Wei D; Wan B; Wang J
    Jpn J Clin Oncol; 2015 Dec; 45(12):1175-81. PubMed ID: 26450700
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
    Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
    Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth.
    Maxwell JP; Wang C; Wiebe N; Yilmaz A; Trpkov K
    Diagn Pathol; 2015 Mar; 10():3. PubMed ID: 25886613
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
    Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
    Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Relevance of the mammalian target of rapamycin pathway in the prognosis of patients with high-risk non-muscle invasive bladder cancer.
    Fahmy M; Mansure JJ; Brimo F; Yafi FA; Segal R; Althunayan A; Hicks J; Meeker A; Netto G; Kassouf W
    Hum Pathol; 2013 Sep; 44(9):1766-72. PubMed ID: 23623586
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of bladder neck involvement on progression in patients with primary non-muscle invasive bladder cancer: a prospective validation study.
    Kobayashi S; Fujii Y; Koga F; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Masuda H; Kihara K
    Urol Oncol; 2014 Jan; 32(1):38.e29-36. PubMed ID: 23702087
    [TBL] [Abstract][Full Text] [Related]  

  • 67. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic and clinicopathologic value of ki-67 and profilin 1 immunohistochemical expression in primary pT1 urothelial bladder cancer.
    Culpan M; Turan T; Ozkanli SS; Zenginkinet T; Kazan O; Ucar T; Atis G; Caskurlu T; Yildirim A
    J Cancer Res Ther; 2021; 17(2):434-442. PubMed ID: 34121689
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
    Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
    Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunohistochemical Differentiation between Urothelial Papillomas and Papillary Neoplasms of Low Malignant Potential of the Urinary Bladder.
    Alrashidy M; Atef A; Baky TA
    Asian Pac J Cancer Prev; 2016; 17(4):1769-72. PubMed ID: 27221850
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
    March-Villalba JA; Ramos-Soler D; Soriano-Sarrió P; Hervás-Marín D; Martínez-García L; Martínez-Jabaloyas JM
    Urol Oncol; 2019 Feb; 37(2):158-165. PubMed ID: 30446453
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Prognostic significance of tenascin-C expression in superficial and invasive bladder cancer.
    Brunner A; Mayerl C; Tzankov A; Verdorfer I; Tschörner I; Rogatsch H; Mikuz G
    J Clin Pathol; 2004 Sep; 57(9):927-31. PubMed ID: 15333651
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Quantitative molecular grading of bladder tumours: a tool for objective assessment of the biological potential of urothelial neoplasias.
    Bollmann D; Bollmann M; Bankfalvi A; Heller H; Bollmann R; Pajor G; Hildenbrand R
    Oncol Rep; 2009 Jan; 21(1):39-47. PubMed ID: 19082441
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?
    Hentschel AE; van Rhijn BWG; Bründl J; Compérat EM; Plass K; Rodríguez O; Henríquez JDS; Hernández V; de la Peña E; Alemany I; Turturica D; Pisano F; Soria F; Čapoun O; Bauerová L; Pešl M; Bruins HM; Runneboom W; Herdegen S; Breyer J; Brisuda A; Scavarda-Lamberti A; Calatrava A; Rubio-Briones J; Seles M; Mannweiler S; Bosschieter J; Kusuma VRM; Ashabere D; Huebner N; Cotte J; Mertens LS; Cohen D; Lunelli L; Cussenot O; Sheikh SE; Volanis D; Coté JF; Rouprêt M; Haitel A; Shariat SF; Mostafid AH; Nieuwenhuijzen JA; Zigeuner R; Dominguez-Escrig JL; Hacek J; Zlotta AR; Burger M; Evert M; Hulsbergen-van de Kaa CA; van der Heijden AG; Kiemeney LALM; Soukup V; Molinaro L; Gontero P; Llorente C; Algaba F; Palou J; N'Dow J; Babjuk M; van der Kwast TH; Sylvester RJ
    Urol Oncol; 2020 May; 38(5):440-448. PubMed ID: 31704141
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Prognostic significance of atypical papillary urothelial hyperplasia.
    Swierczynski SL; Epstein JI
    Hum Pathol; 2002 May; 33(5):512-7. PubMed ID: 12094376
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Impact of p53 and Ki-67 in predicting recurrence and progression of superficial (pTa and pT1) urothelial cell carcinomas of urinary bladder.
    Kilicli-Camur N; Kilicaslan I; Gulluoglu MG; Esen T; Uysal V
    Pathol Int; 2002 Jul; 52(7):463-9. PubMed ID: 12167105
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic value of morphometry in low grade papillary urothelial bladder neoplasms.
    Ramos D; Ruiz A; Morell L; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
    Anal Quant Cytol Histol; 2004 Oct; 26(5):285-94. PubMed ID: 15560535
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer.
    Kobayashi S; Koga F; Kajino K; Yoshita S; Ishii C; Tanaka H; Saito K; Masuda H; Fujii Y; Yamada T; Kihara K
    J Magn Reson Imaging; 2014 Jan; 39(1):172-8. PubMed ID: 23589321
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Reduced CD151 expression is related to advanced tumour stage in urothelial bladder cancer.
    Minner S; De Silva C; Rink M; Dahlem R; Chun F; Fisch M; Höppner W; Wagner W; Bokemeyer C; Terracciano L; Simon R; Sauter G; Wilczak W
    Pathology; 2012 Aug; 44(5):448-52. PubMed ID: 22772340
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
    Ben Abdelkrim S; Rammeh S; Ziadi S; Tlili T; Jaidane M; Mokni M
    J Immunoassay Immunochem; 2014; 35(4):358-67. PubMed ID: 24624938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.